CorMedix Inc. (NASDAQ: CRMD) saw its stock price surge 5.20% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results, which significantly exceeded analyst expectations.
The biopharmaceutical company reported earnings per share (EPS) of $0.30, surpassing the consensus estimate of $0.24 by 25%. This marks a substantial improvement from the $0.25 loss per share reported in the same quarter last year. CorMedix's revenue also impressed, coming in at $39.08 million, beating analyst projections of $36 million by 8.55%.
Investors were further encouraged by CorMedix's strong cash position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Additionally, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half sales guidance range of $62 million to $70 million. This positive financial performance and forward-looking statement likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.